Tumor News and Research

RSS

Scientists discover metabolite fueling aggressive brain tumor growth

Virtually all high-grade, aggressive gliomas in adults accumulate massive amounts of a metabolite called guanidinoacetate (GAA) that overstimulates nearby neurons and promotes tumor growth, according to new research from scientists at Children’s Medical Center Research Institute at UT Southwestern (CRI) published in Cell.

18 Sep 2026

NUS scientists harness magnetic pulses to reprogram immune cells to fight breast cancer

Researchers from the National University of Singapore (NUS) have demonstrated an innovative approach for targeted breast cancer therapy using pulsed electromagnetic fields (PEMFs).

18 Sep 2026

Sex-specific biological clocks reveal how aging differs across the body in women and men

Researchers developed 38 sex-specific biological aging clocks across 15 organ systems, finding differences between females and males in genetic architecture, molecular signatures, disease associations, and mortality patterns. Brain aging clocks were linked to progression from mild cognitive impairment to Alzheimer’s disease in both sexes and to sex-dependent cognitive trajectories among solanezumab-treated A4 participants, while the authors stressed that sex-pooled and sex-interaction models remain complementary approaches.

17 Sep 2026

Scientists reveals how cancer-causing p53 mutations remain invisible to the immune system

One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see.

17 Sep 2026

Existing anti-seizure drug slows the growth of diffuse midline gliomas

An existing anti-seizure drug slows the growth of a devastating group of childhood cancers, new Stanford Medicine-led research has shown.

17 Sep 2026

Salk scientists demonstrate B cells directly enhance killer T cell function

Cancer is the second leading cause of death in the United States, according to a 2026 Cancer Research Institute report. Cancer biologists are keenly aware of this statistic, as it drives them to innovations that revolutionize cancer care-innovations like immunotherapy.

17 Sep 2026

Shatavari may affect more than hormones, and the gut could help explain why

A review in Nutrients examined how bioactive compounds in Asparagus racemosus (Shatavari) may influence cognitive health through the microbiota-gut-brain axis, estrogen-related signaling, neuroinflammation, oxidative stress, and neurotransmitter regulation. Evidence from computational, cellular, animal, and limited human studies suggests several plausible biological pathways, but key questions remain about bioavailability, brain exposure, dosing, and clinical efficacy.

16 Sep 2026

Machine learning improves cancer cell detection through light scattering

Cytological tests are a common method of screening cancer cells from stained cell samples. Using a microscope, pathologists examine cells collected from bodily fluids, looking for tell-tale signs of malignancy like enlarged nuclei or abnormal cell shapes.

16 Sep 2026

Scientists tested how much whole grain makes a difference. The answer was not simply “more”

A meta-analysis of 87 randomized trials found that increasing whole-grain intake was associated with improvements in several cardiometabolic risk factors, although many individual changes were small or clinically unimportant. Dose-response analyses suggested that the magnitude of the effects varied by outcome and intake level, with limited evidence at very high intakes.

16 Sep 2026

Study establishes foundational landscape of tumor evolution in bladder cancer

A new study published in Nature has established the foundational landscape of tumor evolution in bladder cancer and differences in the cancer subtypes, which could point toward better diagnosis and treatment of the disease.

16 Sep 2026

New AACR report outlines future of cutting-edge cancer research

Today, the American Association for Cancer Research (AACR) released the 16th edition of its annual Cancer Progress Report.

16 Sep 2026

Cannabis-derived nanovesicles showed early antitumor potential in mice

Researchers developed a Cannabis sativa hairy root culture system that produced stable plant-derived nanovesicles capable of promoting dendritic cell maturation and activating T-cell responses through TLR2- and TLR4-associated signaling. Oral administration also restored selected immune responses in immunosuppressed mice and suppressed tumor growth in an E.G7 lymphoma model, providing preliminary evidence for their immunomodulatory and antitumor potential.

15 Sep 2026

Genomic profiling uncovers distinct TP53 and PI3K pathways across tumor budding grades

A newly proposed International Association for the Study of Lung Cancer (IASLC) tumor budding-based grading system successfully identified patients with resected lung squamous cell carcinoma (SqCC) at higher risk of poor outcomes and showed potential to help guide selection for adjuvant chemotherapy, according to research presented at the IASLC 2026 World Conference on Lung Cancer on Lung Cancer. (WCLC).

15 Sep 2026

Stage 1 findings support continued pivotal phase evaluation of gotistobart

Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving docetaxel, according to updated findings from Stage 1 of the Phase 3 PRESERVE-003 trial.

15 Sep 2026

Research identifies novel prognostic biomarkers for class II and III BRAF-altered cancers

Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and genomic characteristics, with class III alterations potentially associated with worse prognosis, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer

Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.

15 Sep 2026

Sacituzumab govitecan combination misses progression-free survival endpoint in metastatic NSCLC

Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) and PD-L1 tumor proportion score (TPS) of 50% or greater, according to primary results from the Phase 3 EVOKE-03/KEYNOTE-D46 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Ivonescimab shows significant survival benefit for patients with PD-L1-positive NSCLC

Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to a prespecified interim analysis of the phase 3 HARMONi-2 trial presented today at the IASLC 2026 World Conference on Lung Cancer.

14 Sep 2026

MD Anderson trial challenges local consolidative therapy paradigm in NSCLC

Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), including those with oligometastatic disease, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination

The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase 1b/2 BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Tumor News and Research

Scientists discover metabolite fueling aggressive brain tumor growth

NUS scientists harness magnetic pulses to reprogram immune cells to fight breast cancer

Sex-specific biological clocks reveal how aging differs across the body in women and men

Scientists reveals how cancer-causing p53 mutations remain invisible to the immune system

Existing anti-seizure drug slows the growth of diffuse midline gliomas

Salk scientists demonstrate B cells directly enhance killer T cell function

Shatavari may affect more than hormones, and the gut could help explain why

Machine learning improves cancer cell detection through light scattering

Scientists tested how much whole grain makes a difference. The answer was not simply “more”

Study establishes foundational landscape of tumor evolution in bladder cancer

New AACR report outlines future of cutting-edge cancer research

Cannabis-derived nanovesicles showed early antitumor potential in mice

Genomic profiling uncovers distinct TP53 and PI3K pathways across tumor budding grades

Stage 1 findings support continued pivotal phase evaluation of gotistobart

Research identifies novel prognostic biomarkers for class II and III BRAF-altered cancers

Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer

Sacituzumab govitecan combination misses progression-free survival endpoint in metastatic NSCLC

Ivonescimab shows significant survival benefit for patients with PD-L1-positive NSCLC

MD Anderson trial challenges local consolidative therapy paradigm in NSCLC

Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News